Search

Reset

Status

Medical Condition

Displaying 1 - 1 of 1

Study of OCR/RTX vs. Diroximel for Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)

Condition: Neurological Disorders / Multiple Sclerosis
Investigator: Rebecca Straus Farber, MD
Status: Closed
The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on Ocrelizumab/Rituximab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after last Ocrelizumab (OCR) or Rituximab (RTX) dose, prior to…
Read More